{
    "nctId": "NCT04997941",
    "briefTitle": "Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients",
    "officialTitle": "Higher Dose taMOxifen in Premenopausal bREast Cancer Patients: a preoperaTive Window Trial (MORE-T Trial)",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Premenopausal Breast Cancer, Hormone Receptor-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 238,
    "primaryOutcomeMeasure": "Changes in Ki-67 level",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histopathologically and immunohistochemically confirmed ER+ and HER2- Premenopausal BC patients\n2. Tumor size \\>0.5cm on USG\n3. Stage I-IIIA BC and planned curative surgery\n4. ECOG 0-2\n5. Patients with adequate bone marrow function\n\n   - Hemoglobin \\> 10 g/dL, Plt \\> 100,000/mm3\n6. Patients with adequate kidney function\n\n   - serum Cr \u2264 1.4 mg/dL\n7. Patients with adequate liver function\n\n   * Bilirubin: \u2264 1.5 times of upper normal limit\n   * AST/ALT: \u2264 1.5 times of upper normal limit\n   * Alkaline phosphatase: \u2264 1.8 times of upper normal limit\n8. Patients who decided to voluntarily participate in this trial with written informed consent\n9. Premenopausal women : women who has not removed both ovaries, women who had menses in recent 1 year and FSH level is less than 30mIU/ml\n\nExclusion Criteria:\n\n1. Previous history of ipsilateral invasive breast cancer, in situ lesion\n2. Previous history of chemotherapy or endocrine therapy on contralateral BC for the past 2 years\n3. Patients who has distant metastasis\n4. Patients who is pregnant or breastfeeding\n5. Hormon receptor negative BC\n6. Her-2 positive BC\n7. Diagnosed pituitary adenoma\n8. Women who has endometriosis, unknown vaginal bleeding\n9. Inability to understand and willingness to sign a written informed consent\n10. Patients with endometriosis or unexplained vaginal bleeding\n11. Patients with a history of bleeding constitution, coagulopathy, or thromboembolism\n12. Patients who have administered a CYP3A inhibitor or inducer, CYP2D6 inhibitor, etc. within 4 weeks prior to randomization",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT"
}